1 nts in hospitals that had never administered
alvimopan.
2 s received alvimopan and 463 patients had no
alvimopan.
3 Alvimopan (
0.1-3 mg/kg) or methylnaltrexone (100 mg/kg)
4 Under these conditions,
alvimopan (
1 and 3 mg/kg) also significantly improved de
5 Alvimopan (
1 and 3 mg/kg) significantly reversed this de
6 t modest affinity MOR antagonist weaker than
alvimopan (
1).
7 ge order written was also accelerated in the
alvimopan 12 mg group (HR = 1.42; P = 0.003) with a mean
8 andomized (1:1:1) to receive alvimopan 6 mg,
alvimopan 12 mg, or placebo orally > or =2 hours before
9 overy of GI function was accelerated for the
alvimopan 6 mg (hazard ratio [HR] = 1.28; P < 0.05) and
10 Randomized BR patients received
alvimopan 6 mg (n = 397), 12 mg (n = 413), or placebo (n
11 terectomy were randomized (1:1:1) to receive
alvimopan 6 mg, alvimopan 12 mg, or placebo orally > or
12 Alvimopan (
6 or 12 mg) significantly accelerated GI reco
13 Alvimopan,
a novel, peripherally active mu-opioid recept
14 The effects of
alvimopan,
a novel, selective, and peripherally acting m
15 In clinical trials,
alvimopan--
a peripherally acting mu-opioid receptor anta
16 Alvimopan accelerated GI recovery and time to hospital d
17 Alvimopan administration as an element of enhanced recov
18 atients were included; 197 patients received
alvimopan and 463 patients had no alvimopan.
19 gands, we synthesized dehydro derivatives of
alvimopan and found compound (28f), a selective but mode
20 Our independent study evaluated
alvimopan as it is used in actual hospital practice in t
21 A total of 528 patients received
alvimopan both pre- and postoperatively.
22 s among patients who had alvimopan versus no
alvimopan by adjusting for demographic, clinical, and tr
23 ICU stay (0.3 vs 0.6 days) were lower in the
alvimopan group (P </= 0.003 for each).
24 In unadjusted analysis, the
alvimopan group had a faster return of bowel function, s
25 Patients who received
alvimopan had significantly lower incidence of prolonged
26 Alvimopan has been shown to reduce incidence of postoper
27 By accelerating postoperative recovery,
alvimopan has the potential to benefit patients and heal
28 Alvimopan is a novel opioid receptor antagonist in devel
29 These results suggest that
alvimopan is cost-effective in the setting of enhanced r
30 tudy suggests that the actual utilization of
alvimopan leads to a reduction in prolonged ileus and LO
31 clinical benefit reported to be afforded by
alvimopan may be in part mediated via inhibition of an e
32 s from hospitals that had never administered
alvimopan (
n = 1833) and used propensity matching to man
33 008 in hospitals that would later administer
alvimopan (
n = 270).
34 Each
alvimopan patient was exact matched (surgical procedure,
35 and estimated direct cost were lower for all
alvimopan patients and after laparoscopic and open BR (L
36 rospective subset analysis of BR patients in
alvimopan phase III trials was performed.
37 Alvimopan reduces the consequences of POI after BR.
38 Alvimopan significantly accelerated GI recovery in BR pa
39 Alvimopan significantly accelerated time to DCO written
40 We hypothesized that
alvimopan significantly decreases incidence of prolonged
41 On average,
alvimopan-
treated patients had a lower incidence of mort
42 Alvimopan-
treated patients had reduced postoperative mor
43 spirometry, early nasogastric tube removal,
alvimopan usage, and judicious jejunostomy tube feeding,
44 es and hospital costs among patients who had
alvimopan versus no alvimopan by adjusting for demograph
45 Alvimopan was approved by the Food and Drug Administrati
46 After adjustment,
alvimopan was associated with a faster return of bowel f
47 With adjustment,
alvimopan was associated with a shorter length of stay b
48 However, the effects of
alvimopan were less pronounced when administered followi